IL1B and colon carcinoma: In support of the idea that BC dampens excess immune reactivity, a study using human colonic carcinoma cells (HT-29) showed that treatment with BC inhibited IL-1β-induced IL-8 expression, suppressed IL-1β-induced nuclear factor kappa beta (NFκβ) activation, and inhibited the degradation of inhibitor protein NFκβ [73], suggesting that BC may protect against intestinal inflammation by inhibiting the NFκβ pathway.